LONDON - Virax Biolabs Group Limited (NASDAQ: VRAX), a biotech firm specializing in viral disease diagnostics, has extended its exclusive distribution partnership with Cosmos Health Inc. (NASDAQ: COSM) to market its Mpox Virus Real-Time PCR Detection Kits in the Gulf Cooperation Council (GCC) territories. This agreement builds upon Virax's existing distribution rights in Greece, Cyprus, and non-exclusive rights across Europe.
The PCR detection kits, which have received CE marking for European sales and authorization by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), boast a sensitivity of 96.7% and specificity of 93.72%. Results from the kits are available in under 70 minutes, providing a swift tool for healthcare professionals in the management of the Mpox virus.
James Foster, CEO of Virax Biolabs, expressed enthusiasm about the expanded reach provided by the agreement with Cosmos, highlighting the importance of accessible diagnostic tools in containing infectious diseases. Cosmos CEO Greg Siokas echoed this sentiment, noting the sustained demand for Mpox virus detection and the company's readiness to support Virax in serving the GCC region.
The enhanced agreement authorizes Cosmos to import, sell, and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in GCC member states, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
Virax Biolabs is known for developing T-Cell-based test technologies aimed at providing an immunology profiling platform, which can be crucial in diagnosing and treating post-viral syndromes and immune dysregulation conditions.
Cosmos Health, a diversified healthcare group, has a portfolio that spans pharmaceuticals, nutraceuticals, and a presence in telehealth services. The company's expansion efforts are supported by its manufacturing capabilities, certified by European Good Manufacturing Practices, and a global distribution network.
This partnership extension is expected to enhance the availability of critical diagnostic solutions in the GCC, contributing to the broader efforts to monitor and manage the spread of the Mpox virus.
The information is based on a press release statement from Virax Biolabs.
In other recent news, Cosmos Health Inc. has achieved several significant milestones. The healthcare group has expanded its distribution of mpox virus detection kits to the Gulf Cooperation Council countries, in partnership with Virax Biolabs. This move is particularly crucial given the World Health Organization's recent declaration of the mpox outbreak as a public health emergency.
In addition, Cosmos Health has regained compliance with Nasdaq's Listing Rule 5250(c)(1) after submitting overdue reports. The company has also initiated sales of its C-Scrub product in the German market and secured a distribution partnership with ProMed Trading Company for the Sky Premium Life supplement range in Qatar.
Cosmos Health's subsidiary, Cana Laboratories, has completed the first phase of manufacturing upgrades, potentially generating over $10 million in annual gross profit at full capacity by 2025. The company has also secured contracts with Provident Pharmaceuticals for the production of several pharmaceutical products, totaling 5.02 million units.
However, despite these positive developments, Cosmos Health has faced compliance issues with Nasdaq due to delayed report submissions, which the company is committed to rectifying. These are recent developments in Cosmos Health's journey.
InvestingPro Insights
Virax Biolabs' strategic partnership with Cosmos Health Inc. (NASDAQ: COSM) for the distribution of Mpox Virus Real-Time PCR Detection Kits in the GCC is a key development for both companies. As they collaborate to meet the healthcare demands within the region, it's important to consider Cosmos Health's financial health and market performance, as represented by recent InvestingPro data and insights.
InvestingPro Data shows that Cosmos Health has a market capitalization of $17.07 million, reflecting the size of the company in the financial market. Despite the challenges, the company has managed to maintain a revenue growth of 15.73% over the last twelve months as of Q2 2024, demonstrating its ability to increase sales. However, the company's financials also reveal a gross profit margin of 8.05%, which is relatively low and could indicate challenges in maintaining profitability.
InvestingPro Tips highlight that Cosmos Health operates with a significant debt burden and is quickly burning through cash, which are crucial factors for investors to consider, especially in the context of expanding operations and partnerships. Moreover, the stock has experienced high volatility and has taken a significant hit over the last week, which could be a concern for short-term investors.
For those looking at the longer-term picture, it's worth noting that analysts do not anticipate the company will be profitable this year, and the stock has not been profitable over the last twelve months. Furthermore, Cosmos Health does not pay a dividend to shareholders, which may influence investment decisions for those seeking regular income from their stock holdings.
Investors interested in a deeper analysis can find additional InvestingPro Tips for Cosmos Health at https://www.investing.com/pro/COSM, which provide further insights into the company's performance and projections. These tips could be particularly valuable in assessing the potential impact of the partnership with Virax Biolabs on Cosmos Health's financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.